Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study

导出原文传递

翻译打印收藏纠错

作者： Younes,A. ^[1] ; Thieblemont,C. ^[2] ; Morschhauser,F. ^[3] ; Flinn,I. ^[4] ; Friedberg,J.W. ^[5] ; Amorim,S. ^[6] ; Hivert,B. ^[7] ; Westin,J. ^[8] ; Vermeulen,J. ^[9] ; Bandyopadhyay,N. ^[10] ; deVries,R. ; Balasubramanian,S. ; Hellemans,P. ; Smit,J.W. ; Fourneau,N. ; Oki,Y.

作者单位： Janssen Research and Development, Beerse, Belgium ^[1] Hematology, Centre Hospitalier Universitaire de Lille, Lille, France ^[2] Sarah Cannon Research Institute, Nashville, TN, United States ^[3] Janssen Research and Development, Springhouse, PA, United States ^[4] Janssen Research and Development, Raritan, NJ, United States ^[5] The University of Texas MD Anderson Cancer Center, Houston, TX, United States ^[6] Memorial Sloan-Kettering Cancer Center, New York, NY, United States ^[7] Hemato-oncology Department, H?pital Saint-Louis, AP-HP, P7 University, Paris, France ^[8] Wilmot Cancer Institute, University of Rochester, Rochester, NY, United States ^[9] Janssen Research and Development, Leiden, Belgium ^[10]

发布时间 2014-10-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览7

The lancet oncology

2014年15卷9期

1019-1026页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study

The lancet oncology

相似文献

The lancet oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study

The lancet oncology

相似文献

The lancet oncology

相关期刊

检索历史清除